logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > LN-145 for recurrent, metastatic or persistent cervical carcinoma

< Back

LN-145 for recurrent, metastatic or persistent cervical carcinoma

Drugs

Cancer and Palliative Care

July 2020


LN-145 is in development for the treatment of recurrent, metastatic or persistent cervical cancer. Recurrent cancer is when the cancer returns months or years after the original treatment; persistent cancer is when the tumour does not respond to treatment or a second tumour develops despite the completion of treatment. Metastatic cancer is when the tumour has spread outside the original tumour site, to other areas of the body. If cervical cancer is recurrent, metastatic or persistent, there are limited treatment options, with treatments usually aiming to alleviate symptoms and improve quality of life.

LN-145 is composed of T-cells (a type of immune cell) that are collected from the patient and grown to large numbers in the laboratory. They are then administered intravenously into the patient alongside IL-2 (a protein that activates T-cells), in order to encourage them to recognise and destroy the tumour. Therefore, if licensed, LN-145 would offer an additional treatment option to patients with recurrent, metastatic or persistent cervical cancer, who currently have limited treatment options.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts